PFE - Pfizer Inc.
| Previous Close | 36.80 |
| Open | 36.91 |
| Bid | 37.08 x 1800 |
| Ask | 37.09 x 2700 |
| Day's Range | 36.89 - 37.26 |
| 52 Week Range | 31.67 - 39.43 |
| Volume | 10,188,306 |
| Avg. Volume | 24,991,293 |
| Market Cap | 220.514B |
| Beta | 0.95 |
| PE Ratio (TTM) | 10.54 |
| EPS (TTM) | 3.52 |
| Earnings Date | May 1, 2018 |
| Forward Dividend & Yield | 1.36 (3.70%) |
| Ex-Dividend Date | 2018-02-01 |
| 1y Target Est | 40.16 |
- MarketWatch•1 hour ago
Wegmans EpiPens out of stock, but no U.S. shortage currently seen, FDA says
In spite of reports that Wegmans pharmacies are out of stock of the EpiPen allergic reaction treatment, the Food and Drug Administration is not currently aware of any U.S. shortage, though the regulator continues to monitor the supply, spokesperson Lauren Smith Dyer. Pfizer , which manufactures the Mylan product through one of its business units, said that it is currently shipping products but supplies may vary from pharmacy to pharmacy.
- Market Realist•2 hours ago
How Johnson & Johnson’s Pharmaceutical Segment Performed in 1Q18
About 49.2% of Johnson & Johnson’s (JNJ) total revenues in 1Q18 came from the pharmaceutical segment, making it the largest revenue contributor for the company. The pharmaceutical business includes revenues from cardiovascular and metabolic products, infectious disease products, immunology products, oncology products, neuroscience products, and pulmonary hypertension products.
- Zacks•3 hours ago
The Zacks Analyst Blog Highlights: Aflac, CenterPoint, Guess', Nordstrom and Pfizer
The Zacks Analyst Blog Highlights: Aflac, CenterPoint, Guess', Nordstrom and Pfizer
- Market Realist•4 hours ago
Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18
Johnson & Johnson (JNJ) reported 8.4% growth in operating revenues and a 4.2% positive impact of foreign exchange to $20.0 billion in 1Q18 as compared to revenues of $17.8 billion during 1Q17. Johnson & Johnson reported growth across all three of its segments: the pharmaceutical segment, the consumer health segment, and the medical devices segment.
- Market Realist•4 hours ago
Eli Lilly and Co.’s Strong Q1 Results, Updated 2018 Guidance
Eli Lilly and Co. (LLY) reported revenues of ~$5.7 billion for 1Q18 today, reflecting 9% growth from 1Q17. The company beat Wall Street analysts’ estimates for earnings-per-share (or EPS) and revenues in 1Q18 and reported EPS of $1.34 on revenues of ~$5.7 billion, compared to an estimated EPS of $1.14 on revenues of ~$5.5 billion.
- Motley Fool•4 hours ago
Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma
It's a lot easier to be patient once those quarterly payments start adding up.
- Motley Fool•23 hours ago
Don't Get Greedy With Novavax, Inc. Stock
Novavax's abysmal track record should be a huge red flag for potential shareholders.
- Market Realist•23 hours ago
Eli Lilly’s 1Q18 Estimates: Revenue Growth Expected
Wall Street analysts expect an ~3.0% increase in Eli Lilly & Co.’s (LLY) 1Q18 revenues to $5.5 billion. Eli Lilly’s products are sold in more than 120 countries, and its international sales comprise ~45.0% of its total revenues. As a result, the company is exposed to currency risk, and foreign exchange is expected to have a positive impact on its overall revenues during 1Q18.
- Market Realist•yesterday
Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings
Eli Lilly & Co. (LLY) is a leading US-based pharmaceutical company with a product portfolio covering human health products and animal health products. Eli Lilly is set to release its 1Q18 earnings on April 24.
Yahoo Finance Video•2 hours agoNEWS BITES: Police look for motive in deadly Toronto van attack, President George H.W. Bush hospitalized, Prince's family suing hospital that treated him
Here’s a quick wrap up of other headlines making news today.
Yahoo Finance Video•2 hours agoHere’s why Amazon won’t go into pharma: hedge fund billionaire
Larry Robbins, CEO of Glenview Capital Management, told investors he doesn’t expect Amazon to move into the drug space. Yahoo Finance’s Alexis Christoforous, Melody Hahm, and Julia La Roche discuss his reasoning.
